INDV
Indivior Pharmaceuticals, Inc.
Healthcare • CIK: 0001625297
Loading...
Market Cap
$3.03B
P/E (TTM)
23.4x
Rev Growth (TTM)
—
Net Margin (TTM)
10.8%
FCF Yield (TTM)
4.2%
FCF Margin (TTM)
10.8%
Cash Flow Health
Free Cash Flow3/8 positive
TTM$128M
Q3 '26
$-59M-142%
Q2 '26
$140M+100%
FCF Margin
TTM10.8%
Q3 '26-18.8%-141%
Sector: 0.0%Top 25%
OCF Margin14.9%
OCF/NI1.38x
CapEx Coverage3.6x
FCF Yield4.2%
FCF Growth (2Y)–
Cash Conversion Cycle
236 days
DSO: 76+DIO: 238−DPO: 79
Capital Allocation & Returns
Balanced
Total Shareholder YieldTTM
TTM2.1%
Div Yield0.0%
+Buyback (TTM)2.1%
Balancing returns with reinvestment
Dividend & Payout Metrics
Dividend Yield (TTM)0.0%
Free Cash Flow (TTM)$128.0M
Stock Repurchases (TTM)$63.0M
Capital Return / FCF49.2%
Est. Dividends Paid (TTM)$0
Shows how management rewards shareholders
Operational Efficiency & Returns
Return on Invested CapitalTTM
365.5%
P25MedianP75
75th pctl (med: 0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
12.6%
Asset Turnover
0.86x
Leverage (1+D/E)
-0.56x
D/E: -1.56x
DuPont: -6.0% ≈ 365.5% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
12.42x
8Q:–
Invested Cap Turn
29.09x
8Q:–
CapEx Intensity
1.2%
8Q:–
CapEx/Depreciation
3.50x
Asset-based ROIC formula
QUARTERLY TRENDS
Last 6 quarters + TTM
| Metric | TTM | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|---|
Revenue | $1.2B | $314.0M↑4.0% | $302.0M↑13.5% | $266.0M↓13.4% | $307.0M↑2.7% | $299.0M↑5.3% | $284.0M |
Operating Income | $227.0M | $43.0M↓40.3% | $72.0M↑9.1% | $66.0M↑43.5% | $46.0M↑31.4% | $35.0M↑129.7% | $-118.0M |
Net Income | $128.0M | $42.0M↑133.3% | $18.0M↓61.7% | $47.0M↑123.8% | $21.0M↓4.5% | $22.0M↑122.7% | $-97.0M |
Operating Cash Flow | $177.0M | $-39.0M↓124.7% | $158.0M↑110.7% | $75.0M↑541.2% | $-17.0M↓950.0% | $2.0M↓97.7% | $88.0M |
Free Cash Flow | $128.0M | $-59.0M↓142.1% | $140.0M↑100.0% | $70.0M↑511.8% | $-17.0M↓240.0% | $-5.0M↓106.0% | $84.0M |
Total Equity | N/A |
Valuation Analysis
Fair Value
Price-to-EarningsTTM
23.4x
Valuation Lenses
Earnings
23.4x
vs – sector
Cash Flow
22.8x
EV/FCF vs –
Growth-Adj
–PEG
N/A
Quality-Adj
0.1P/E per %ROIC
ROIC: 365.5%
Shareholder Returns
Dividend
–
Buyback
2.1%
Total Yield
2.1%
Market Cap$3.03B
EV$2.92B
Multi-angle valuation analysis with sector context
Business Quality & Moat
Overall Quality Score
100/100
Exceptional
Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)
Returns on Capital
Return on Equity (ROE)Below Avg
-45.0%
8Q:–
Return on Invested Capital (ROIC)Top 25%
3.7%
8Q:–
DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)
NOPAT Margin: 12.6%
Asset Turnover: 0.86x
Earnings Quality
Cash Conversion
1.38x
OCF / Net Income ✓
FCF Consistency
–
Positive quarters
Competitive Moat Indicators
Pricing Power
Gross Margin79.4%
Capital Efficiency
Invested Capital Turnover29.09x
Working Capital
Cash Conversion Cycle236 days
Growth Quality & Momentum
Growth Rates
Revenue Growth YoY
N/A
OpInc Growth YoY
22.9%
EPS Growth YoY
N/A
FCF 3Y CAGR
N/A
Margin Quality & Sustainability
High Quality
Profitability Cascade
Gross
79.4%
Operating
19.1%
Top 25% in sector
Net
10.8%
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
0.0 pts
FCF: 10.8% | Net: 10.8%
Quality = stability + cash conversion + low dilution
Balance Sheet & Solvency
Fortress
Net Debt / EBITDA
Net Cash
(0.0x)Net Cash: $123.00M
Interest Coverage
–
+Net cash position: $123.00M
Leverage Metrics
Debt-to-Equity
-1.56x
Balance sheet risk & solvency analysis